SALT LAKE CITY, Nov. 28, 2021 /PRNewswire/ -- Novarad, a
leading provider of medical software, announced today that it has
expanded its strategic partnership with mammography analytics
company, PenRad, Inc. PenRad's automated tracking and reporting
system for lung screening, PenLung will integrate with Novarad's
NovaPACS with enterprise imaging.
The NovaPACS platform is focused on elevating patient health and
efficiently managing workflows by providing a simple yet elegant
solution to reading and reporting. The fully-integrated platform
and its multiple components enable users to view many kinds of
studies from a single workstation.
In addition to the products PenConnect and PenTrac, Novarad will
be offering PenLung, a lung nodule tracking and reporting platform,
as well as PenAlert. PenLung and PenAlert are automated solutions
for reporting CT lung screening results for the nearly 50 separate
abnormality profiles and 30 Lung-RADS combinations for audit and
recall requirements. PenLung also facilitates upload to the
National Lung CT Registry, which is a requirement for each lung
cancer LDCT screening performed.
"We are pleased to be able to add PenLung and PenAlert to the
arsenal of products that arm radiologists with the tools to provide
faster and more accurate diagnoses, which results in better patient
care and reduced patient vulnerability," said David Grandpre, Senior Director of Product at
Novarad. "Recent changes in LDCT lung screening guidelines and an
increase of 37% in payment for outpatient lung imaging will drive
demand for more efficient workflow and analytics programs; NovaPACS
with PenLung fits the bill."
"PenLung Low Dose CT screening software provides radiology
departments optimized workflow benefits and tracking efficiencies
previously only required by women's imaging programs" said
Greg Gustafson, President and CEO of
PenRad Technologies, Inc. Gustafson goes on to say, "the growth of
PenLung is coincident with the expansion of LDCT lung screening
programs across the U.S., and is being driven by the release of new
LDCT screening guidelines. This steady expansion gives us
hope that early detection rates will rise in the coming years."
PenRad and Novarad will be attending the 2021 Radiological
Society of North America (RSNA)
Annual Meeting, scheduled for Nov. 28 – Dec. 2, 2021 in Chicago, Illinois. Visit PenRad at booth #3117
and Novarad at booth #1729 to learn more about this new partnership
and how it can help you meet both current and future healthcare
demands.
About Novarad
Novarad enables healthcare providers to take control of their
medical images through its full diagnostic suite. Ncompass
Enterprise Imaging, along with user-configurable clinical workflow
modules, gives facilities the solutions they need to accelerate the
quality of care while assuring consistent and predictable costs.
The innovative OpenSight augmented reality system overlays medical
images directly onto the patient's body in order to enable accurate
registration for surgical planning. Novarad improves the practice
of medicine by continually developing and refining our advanced
imaging technologies to benefit providers and patients. Visit
Novarad at www.novarad.net for more information.
About PenRad
PenRad, a software provider for enhancing productivity
for: breast imaging - PenRad, LDCT lung screening -
PenLung, general radiology - PenAlert, genetic analysis - PenGen.
PenRad invests in healthcare community in diagnostic technology,
techniques, and analysis. PenRad provides software, and leadership
towards standardization. These include HL7 workgroups, Clinical
Interoperability Modeling Initiative (CIMI), and the
Cancer-Interoperability project supported by the ONC, FDA, CDC,
NCI, NIH and RSNA. For more information, visit the company's
website: www.penrad.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novarad-and-penrad-partner-to-provide-further-diagnostic-tracking-functionality-to-healthcare-providers-301432573.html
SOURCE Novarad Corporation